NCT06177457 - A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions

Healthy Participants

Interventions

DRUG

PF-07293893

PF-07293893 will be administered as tablets every day (QD) over 14 days

DRUG

Placebo

Placebo will be administered as tablets; QD over 14 days

DRUG

Midazolam

Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893

Trial Locations (3)

Pfizer Clinical Research Unit - New Haven, New Haven

Yale University/Magnetic Resonance Research Center (MRRC), New Haven

Pfizer Clinical Research Unit - Brussels, Brussels